Human endogenous retroviruses and cancer prevention: Evidence and prospects

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Cegolon, Luca ^a,b   Salata, Cristiano ^a   Weiderpass, Elisabete ^c,d,e,f   Vineis, Paolo ^b,g   Palù, Giorgio ^a   Mastrangelo, Giuseppe ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF TROMSØ   (Norway)

^d Cancer Registry of Norway ^*  (Norway)

^e KAROLINSKA INSTITUTE   (Sweden)

^f FOLKHÄLSAN RESEARCH CENTER   (Finland)

^g HuGeF Foundation   (Italy)

Author keywords

BCG; Breast cancer; Cancer prevention; Epidemiology; HERV K; Melanoma; Ovarian cancer; Vaccinia; Yellow fever virus vaccine

Indexed keywords

BCG VACCINE; HEPATITIS B VACCINE; MONOCLONAL ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; VACCINIA VACCINE; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN; WART VIRUS VACCINE; YELLOW FEVER VACCINE;

AMINO ACID SEQUENCE; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CELLULAR IMMUNITY; ENDOGENOUS RETROVIRUS; ENVELOPE GENE; GENE EXPRESSION; HUMAN; HUMAN ENDOGENOUS RETROVIRUS K; IMMUNE SYSTEM; LIVER CELL CARCINOMA; LYMPHOMA; MELANOMA; NONHUMAN; OVARY CANCER; RETROPOSON; RISK FACTOR; RISK REDUCTION; SARCOMA; UTERINE CERVIX CANCER; VIRUS REACTIVATION;

ANIMALS; ANTIGENS, VIRAL; BREAST NEOPLASMS; ENDOGENOUS RETROVIRUSES; FEMALE; GENE EXPRESSION REGULATION, VIRAL; HOST-PATHOGEN INTERACTIONS; HUMANS; MALE; MELANOMA; NEOPLASMS; OVARIAN NEOPLASMS; RETROVIRIDAE INFECTIONS; RISK FACTORS; VIRAL VACCINES; VIRUS REPLICATION; YELLOW FEVER; YELLOW FEVER VACCINE;

EID: 84871714941     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-4     Document Type: Article

References (106)

1. Wagner KH, Brath H. A global view on the development of non communicable diseases. Prev Med 2012, 54(Suppl):S38-41.
2. Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 2012, [Epub ahead of print].
3. Maddams J, Brewster D, Gavin A, Steward J, Elliott J, Utley M, Møller H. Cancer prevalence in the United Kingdom: estimates for 2008. Br J Cancer 2009, 101(3):541-7. 10.1038/sj.bjc.6605148, 2720244, 19568236.
4. SEER Cancer Statistics Review, 1975-2005 2007, Bethesda, MD: National Cancer Institute, Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, http://seer.cancer.gov/csr/1975_2005. Accessed July 2008.
5. Warren JL, Yabroff KR, Meekins A, et al. Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst 2008, 100(12):888-897. 10.1093/jnci/djn175, 3298963, 18544740.
6. Mariotto AB, Yabroff KB, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. JNCI 2011, 103:117-123. 10.1093/jnci/djq495, 3107566, 21228314.
7. U.S. Census Bureau, Population Division Interim Projections Consistent With Census 2000 (released March 2004) 2008, Washington D.C: U.S. Census Bureau, Population Division, http://www.census.gov/population/ www/projections/usinterimproj/. Accessed July 2008, U.S. Census Bureau, Population Division.
8. Krone B, Grange JM. Melanoma, Darwinian medicine and the inner world. J Cancer Res Clin Oncol 2010, 136:1787-1794. 10.1007/s00432-010-0949-x, 2962785, 20852885.
9. Rook GA, Dalgleish A. Infection, immunoregulation, and cancer. Immunol Rev 2011, 240:141-159. 10.1111/j.1600-065X.2010.00987.x, 21349092.
10. International Human Genome Sequencing Consortium (IHGSC) Initial sequencing and analysis of the human genome. Nature 2001, 409:860-921. 10.1038/35057062, 11237011, International Human Genome Sequencing Consortium (IHGSC).
11. Kazazian HH. Mobile elements: drivers of genome evolution. Science 2004, 303:1626-1632. 10.1126/science.1089670, 15016989.
12. Griffiths DL. Endogenous retroviruses in the human genome sequence. Genome Biol 2001, 2:1017.1-1017.5.
13. Friedlander A, Patarca R. Endogenous proviruses. Crit Rev Oncog 1999, 10:129-159.
14. Stoye JP. Studies of endogenous retroviruses reveal a continuing evolutionary saga. Nat Rev Microbiol 2012, 10(6):395-406.
15. Bannert N, Kurth R. Retroelements and the human genome: new perspectives on an old relation. Proc Natl Acad Sci USA 2004, 101:14572-14579. 10.1073/pnas.0404838101, 521986, 15310846.
16. Li WH, Gu Z, Wang H, et al. Evolutionary analyses of the human genome. Nature 2001, 409:847-49. 10.1038/35057039, 11237007.
17. Coffin J. Endogenous viruses. RNA Tumor Viruses 1984, 1109-1203. Cold Spring Harbor, NY: Cold Spring Harbor Press, Weiss R, Teich N, Varmus H, Coffin J, 2.
18. Weinberg RA. Origins and roles of endogenous retroviruses. Cell 1980, 22:643-4. 10.1016/0092-8674(80)90537-1, 7460007.
19. Dolittle WF, Sapienza C. Selfish genes, the phenotype paradigm and genome evolution. Nature 1980, 284:601-3. 10.1038/284601a0, 6245369.
20. Orge L, Crick FHC. Selfish DNA. the ultimate parasite. Nature 1980, 284:604-7. 10.1038/284604a0, 7366731.
21. Baltimore D. Retroviruses and retrotransposones: the role of reverse transcription in shaping the eukaryotic genome. Cell 1985, 40:481-82. 10.1016/0092-8674(85)90190-4, 2578883.
22. Temin HM. Origin and general nature of retroviruses. The Retroviridae, Vol 1 1992, 1-18. New York: Plenum Press, Levy JA.
23. Zeyl C, Beli G. Symbiotic DNA in eukaryotic genomes. Trends Ecol EvoI 1996, 11:10-5.
24. Boller K, Schönfeld K, Lischer S, Fischer N, HoVmann A, Kurth R, Tönjes RR. Human endogenous retrovirus HERV-K113 is capable of producing intact viral particles. J Gen Virol 2008, 89(Pt 2):567-572.
25. Schiavetti F, Thonnard J, Colau D, Boon T, Coulie PG. A human endogenous retroviral sequence encoding an antigen recognized on melanoma by cytolytic T lymphocytes. Cancer Res 2002, 62(19):5510-6.
26. Flockerzi A, Burkhardt S, Schempp W, Meese E, Mayer J. Human endogenous retrovirus HERV-K14 family: status, variants, evolution and mobilization of other cellular sequences. J Virol 2005, 79:2941-2949. 10.1128/JVI.79.5.2941-2949.2005, 548434, 15709013.
27. Laufer G, Mayer J, Mueller BF, Mueller-Lantzsch N, Ruprecht K. Analysis of transcribed human endogenous retrovirus W env loci clariWes the origin of multiple sclerosis-associated env sequences. Retrovirology 2009, 6:37-53. 10.1186/1742-4690-6-37, 2672075, 19368703.
28. Moyes D, Griffithsm DJ, Venables PJ. Insertional polymorphisms. A new lease of life for endogenous retrovirus in human disease. Trends Genet 2007, 2:326-333.
29. Ryan FP. Virolution 2009, New York: Harper Collins.
30. Gogvadze E, Stukacheva E, Buzdin A, Sverdlov E. Human specific modulation of transcriptional activity provided by endogenous retroviral insertions. J Virol 2009, 83:6098-6105. 10.1128/JVI.00123-09, 2687385, 19339349.
31. Kalter SS, Helmke RJ, Heberling RL, Panigel M, Fowler AK, Strickland JE, Hellman A. Brief communication: C-type particles in normal human placentas. J Natl Cancer Inst 1973, 50:1081-1084.
32. Rote NS, Chakrabarti S, Stetzer BP. The role of human endogenous retroviruses in trophoblast diVerentiation and placental development. Placenta 2004, 25:673-683. 10.1016/j.placenta.2004.02.008, 15450384.
33. Larsson E, Andersson G. Beneficial role of human endogenous retroviruses: facts and hypotheses. Scand J Immunol 1998, 48:329-338. 10.1046/j.1365-3083.1998.00428.x, 9790301.
34. Hohenadl C, Germaier H, Walchner M, Hagenhofer M, Herrmann M, Sturzl M, Kind P, Hehlmann R, Erfle V, Leib-Mosch C. Transcriptional activation of endogenous retroviral sequences in human epidermal keratinocytes by UVB irradiation. J Invest Dermatol 1999, 113:587-594. 10.1046/j.1523-1747.1999.00728.x, 10504445.
35. Khan AS, Muller J, Sears JF. Early detection of endogenous retroviruses in chemically induced mouse cells. Virus Res 2001, 79:39-45. 10.1016/S0168-1702(01)00280-5, 11551644.
36. Ono M, Kawakami M, Ushikubo H. Stimulation of expression of the human endogenous retrovirus genome by female steroid hormones in human breast cancer cell line T47D. J Virol 1987, 6:2059-2062.
37. Katsumata K, Ikeda H, Sato M, Ishizu A, Kawarada Y, Kato H, Wakisaka A, Koike T, Yoshiki T. Cytokine regulation of env gene expression of human endogenous retrovirus-R in human vascular endothelial cells. Clin Immunol 1999, 93:75-80. 10.1006/clim.1999.4762, 10497013.
38. Krone B, Kölmel KF, Henz BM, Grange JM. Protection against melanoma by vaccination with Bacille Calmette-Guerin (BCG) and/or vaccinia: an epidemiology-based hypothesis on the nature of a melanoma risk factor and its immunological control. Eur J Cancer 2005, 41(1):104-17. 10.1016/j.ejca.2004.08.010, 15617995.
39. Gimenez J, Montgiraud C, Pichon JP, Bonnaud B, Arsac M, Ruel K, Bouton O, Mallet F. Custom human endogenous retroviruses dedicated microarray identiWes self-induced HERV-W family elements reactivated in testicular cancer upon methylation control. Nucl Acids Res 2010, 38:2229-2246. 10.1093/nar/gkp1214, 2853125, 20053729.
40. Stengel S, Fiebig U, Kurth R, Denner J. Regulation of human endogenous retrovirus-K expression in melanomas by CpG methylation. Genes Chromosom Cancer 2010, 49:401-411. 10.1002/gcc.20751, 20095041.
41. Dolei A, Perron H. The multiple sclerosis-associated retrovirus and its HERV-W endogenous family: a biological interface between virology, genetics and immunology in human physiology and disease. J Neurovirol 2009, 15:4-13. 10.1080/13550280802448451, 19039700.
42. Gifford R, Tristem M. The evolution distribution and diversity of endogenous retroviruses. Virus Genes 2003, 26:291-315. 10.1023/A:1024455415443, 12876457.
43. Belshaw R, Dawson AL, Woolven-Allen J, Redding J, Burt A, Tristem M. Genomewide screening reveals high levels of insertional polymorphism in the human endogenous retrovirus family HERV-K (HML-2): implications for present day activity. J Virol 2005, 79:12507-12514. 10.1128/JVI.79.19.12507-12514.2005, 1211540, 16160178.
44. Tristem M. Identification and characterization of novel human endogenous retrovirus families by phylogenetic screening of the human genome mapping project database. J Virol 2000, 74:3715-30. 10.1128/JVI.74.8.3715-3730.2000, 111881, 10729147.
45. Löwer R, Lower J, Kurth R. The viruses in all of us: characteristics and biological significance of human endogenous retrovirus sequences. Proc Natl Acad Sci U S A 1996, 93:5177-5184. 10.1073/pnas.93.11.5177, 39218, 8643549.
46. Sverdlov ED. Retroviruses and primate evolution. Bioessays 2000, 22:161-171. 10.1002/(SICI)1521-1878(200002)22:2<161::AID-BIES7>3.0.CO;2-X, 10655035.
47. Mayer J, Sauter M, Rácz A, Scherer D, Mueller-Lantzsch N, Meese E. An almost-intact human endogenous retrovirus K on human chromosome 7. Nat Genet 1999, 21:257-8. 10.1038/6766, 10080172.
48. Hughes JF, Coffin JM. Human endogenous retroviral elements as indicators of ectopic recombination events in the primate genome. Genetics 2005, 171:1183-1194. 10.1534/genetics.105.043976, 1456821, 16157677.
49. Löwer R, Boller K, Hasenmaier B, Korbmacher C, Muller-Lantzsch N, Lower J, Kurth R. Identification of human endogenous retroviruses with complex mRNA expression and particle formation. Proc Natl Acad Sci U S A 1993, 90:4480-4484. 10.1073/pnas.90.10.4480, 46535, 8506289.
50. Muster T, Waltenberger A, Grassauer A, Hirschl S, Caucig P, Romirer I, Fodinger D, Seppele H, Schanab O, Magin-Lachmann C, Lower R, Jansen B, Pehamberger H, Wolff K. An endogenous retrovirus derived from human melanoma cells. Cancer Res 2003, 63:8735-8741.
51. Ono M. Molecular cloning and long terminal repeat sequences of human endogenous retrovirus genes related to types A and B retrovirus genes. J Virol 1986, 58(3):937-944. 253002, 3009897.
52. Flockerzi A, Ruggieri A, Frank O, Sauter M, Maldener E, Kopper B, Wullich B, Seifarth W, Müller-Lantzsch N, Leib-Mösch C, Meese E, Mayer J. Expression patterns of transcribed human endogenous retrovirus HERV-K(HML-2) loci in human tissues and the need for a HERV Transcriptome Project. BMC Genomics 2008, 9:354. 10.1186/1471-2164-9-354, 2525661, 18664271.
53. Sarid R, Gao SJ. Viruses and human cancer: from detection to causality. Cancer Lett 2011, 305(2):218-27. 10.1016/j.canlet.2010.09.011, 3037427, 20971551.
54. Seifarth W, Baust C, Murr A, Skladny H, Krieg-Schneider F, Blusch J, Werner T, Hehlmann R, Leib-Mosch C. Proviral structure, chromosomal location, and expression of HERV-K-T47D, a novel human endogenous retrovirus derived from T47D particles. J Virol 1998, 72:8384-8391. 110222, 9733890.
55. Büscher K, Trefzer U, Hofmann M, Sterry W, Kurth R, Denner J. Expression of human endogenous retrovirus K in melanomas and melanoma cell lines. Cancer Res 2005, 65:4172-4180. 10.1158/0008-5472.CAN-04-2983, 15899808.
56. Contreras-Galindo R, Kaplan MH, Leissner P, Verjat T, Ferlenghi I, Bagnoli F, Giusti F, Dosik MH, Hayes DF, Gitlin SD, Markovitz DM. Human endogenous retrovirus K (HML-2) elements in the plasma of people with lymphoma and breast cancer. J Virol 2008, 82:9329-36. 10.1128/JVI.00646-08, 2546968, 18632860.
57. Wang-Johanning F, Rycaj K, Plummer JB, Li M, Yin B, Frerich K, Garza JG, Shen J, Lin K, Yan P, Glynn SA, Dorsey TH, Hunt KK, Ambs S, Johanning GL. Immunotherapeutic potential of anti-human endogenous retrovirus-k envelope protein antibodies in targeting breast tumors. J Natl Cancer Inst 2012, 104(3):189-210. 10.1093/jnci/djr540, 22247020.
58. Wang-Johanning F, Radvanyi L, Rycaj K, Plummer JB, Yan P, Jagannadha Sastry K, Piyathilake C, Hunt KK, Johanning GL. Human Endogenous Retrovirus K Triggers an Antigen-Specific Immune Response in Breast Cancer Patients. Cancer Res 2008, 68(14):5869-77. 10.1158/0008-5472.CAN-07-6838, 18632641.
59. Wang-Johanning F, Frost AR, Jian B, Epp L, Lu DW, Johanning GL. Quantitation of HERV-K env gene expression and splicing in human breast cancer. Oncogene 2003, 22:1528-1535. 10.1038/sj.onc.1206241, 12629516.
60. Wang-Johanning F, Frost AR, Johanning GL, Khazaeli MB, LoBuglio AF, Shaw DR, Strong TV. Expression of human endogenous retrovirus k envelope transcripts in human breast cancer. Clin Cancer Res 2001, 7(6):1553-60.
61. Wang-Johanning F, Frost AR, Jian B, Epp L, Lu DW, Johanning GL. Expression of multiple human endogenous retrovirus surface envelope proteins on ovarian cancer. Int J Cancer 2007, 120(1):81-90. 10.1002/ijc.22256, 17013901.
62. Serafino A, Balestrierib E, Pierimarchia P, Matteucci C, Moroni G, Oricchio E, Rasia G, Mastino A, Spadafora C, Garaci E, Sinibaldi Vallebona P. The activation of human endogenous retrovirus K (HERV-K) is implicated in melanoma cell malignant transformation. Exp Cell Res 2009, 315:849-862. 10.1016/j.yexcr.2008.12.023, 19167380.
63. Singh S, Kaye S, Gore ME, McClure MO, Bunker CB. The role of human endogenous retroviruses in melanoma. Br J Dermatol 2009, 161(6):1225-31. Epub 2009 Jul, 10.1111/j.1365-2133.2009.09415.x, 19785608.
64. Herbst H, Sauter M, Mueller-Lantzsch N. Expression of human endogenous retrovirus K elements in germ cell and trophoblastic tumors. Am J Pathol 1996, 149:1727-1735. 1865275, 8909261.
65. Depil S, Roche C, Dussart P, Prin L. Expression of a human endogenous retrovirus, HERV-K, in the blood cells of leukaemia patients. Leukemia 2002, 16:254-259. 10.1038/sj.leu.2402355, 11840292.
66. Boyd MT, Foley B, Brodsky I. Evidence for copurification of HERV-K-related transcripts and a reverse transcriptase activity in human platelets from patients with essential thrombocythemia. Blood 1990, 90:4022-4030.
67. Ishida T, Obata Y, Ohara N, et al. Identification of the HERV-K gag antigen in prostate cancer by SEREX using autologous patient serum and its immunogenicity. Cancer Immun 2008, 8:15. 2935773, 19006261.
68. Ahn K, Kim HS. Structural and quantitative expression analyses of HERV gene family in human tissues. Mol Cells 2009, 28(2):99-103. 10.1007/s10059-009-0107-y, 19669627.
69. Schanab O, Humer J, Gleiss A, et al. Expression of human endogenous retrovirus K is stimulated by ultraviolet radiation in melanoma. Pigment Cell Melanoma Res 2011, 24(4):656-65. 10.1111/j.1755-148X.2011.00860.x, 21501418.
70. Reiche J, Pauli G, Ellerbrok H. Differential expression of human endogenous retrovirus K transcripts in primary human melanocytes and melanoma cell lines after UV irradiation. Melanoma Res 2010, 20(5):435-40.
71. Gabriel U, Steidler A, Trojan L, et al. Smoking increases transcription of human endogenous retroviruses in a newly established in vitro cell model and in normal urothelium. AIDS Res Hum Retroviruses 2010, 26(8):883-8. 10.1089/aid.2010.0014, 20666582.
72. Contreras-Galindo R, López P, Vélez R, Yamamura Y. HIV-1 infection increases the expression of human endogenous retroviruses type K (HERV-K) in vitro. AIDS Res Hum Retroviruses 2007, 23(1):116-22. 10.1089/aid.2006.0117, 17263641.
73. Horsley V, Pavlath GK. NFAT: ubiquitous regulator of cell differentiation and adaptation. J Cell Biol 2002, 156:771-774. 10.1083/jcb.200111073, 2173310, 11877454.
74. Kershaw MH, Hsu C, Mondesire W, et al. Immunizatiom against endogenous retroviral tumour-associated antigens. Cancer Res 2001, 61(21):7920-4. 2247477, 11691813.
75. Sciamanna I, Landriscina M, Pittoggi C, Quirino M, Mearelli C, Beraldi R, Mattei E, Serafino A, Cassano A, Sinibaldi-Vallebona P, Garaci E, Barone C, Spadafora C, et al. Inhibition of endogenous reverse transcriptase antagonizes human tumor growth. Oncogene 2005, 24:3923-31. 10.1038/sj.onc.1208562, 15806170.
76. Mangeney M, Pothlichet J, Renard M, et al. Endogenous retrovirus expression is required for murine melanoma tumor growth in vivo. Cancer Res 2005, 65:2588-91. 10.1158/0008-5472.CAN-04-4231, 15805254.
77. Oricchio E, Sciamanna I, Beraldi R, et al. Distinct roles for LINE-1 and HERV-K retroelements in cell proliferation, differentiation and tumor progression. Oncogene 2007, 26:4226-33. 10.1038/sj.onc.1210214, 17237820.
78. Humer J, Waltenberger A, Grassauer A, et al. Identification of a melanoma marker derived from melanoma-associated endogenous retroviruses. Cancer Res 2006, 66:1658-63. 10.1158/0008-5472.CAN-05-2452, 16452225.
79. Hahn S, Ugurel S, Hanschmann KM, et al. Serological response to human endogenous retrovirus K in melanoma patients correlates with survival probability. AIDS Res Hum Retroviruses 2008, 24:717-23. 10.1089/aid.2007.0286, 18462078.
80. Grange JM, Krone B, Kölmel KF, Mastrangelo G. Can prior vaccinations against certain infections confer protection against developing melanoma?. MJA 2009, 191(9):478-479.
81. Koelmel KF, Gefeller O, Haferkamp B. Febrile infections and malignant melanoma: results of a case-control study. Melanoma Res 1992, 2:207-211. 10.1097/00008390-199209000-00009, 1450674.
82. Krone B, Kölmel KF, Grange JM, Mastrangelo G, Henz BM, Botev IN, Niin M, Seebacher C, Lambert D, Shafir R, Kokoschka EM, Kleeberg UR, Gefeller O, Pfahlberg A. Impact of vaccinations and infectious diseases on the risk of melanoma-evaluation of an EORTC case-control study. Eur J Cancer 2003, 39(16):2372-8. 10.1016/S0959-8049(03)00625-7, 14556930.
83. Mastrangelo G, Krone B, Fadda E, Buja A, Grange JM, Rausa G, de Vries E, Koelmel KF. Does yellow fever 17D vaccine protect against melanoma?. Vaccine 2009, 27(4):588-91. 10.1016/j.vaccine.2008.10.076, 19010368.
84. Hodges-Vazquez M, Wilson JP, Hughes H, Garman P. The yellow fever 17D vaccine and risk of malignant melanoma in the United States military. Vaccine 2012, 30:4476-9. 10.1016/j.vaccine.2012.04.074, 22561488.
85. Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. Epidemiology 1999, 10(1):37-48. 10.1097/00001648-199901000-00008, 9888278.
86. De Parseval N, Alkabbani H, Heidmann T. The long terminal repeats of the HERV-H human endogenous retrovirus contain binding sites for transcriptional regulation by the Myb protein. J Gen Virol 1999, 80(Part 4):841-5.
87. Lee WJ, Kwun HJ, Kim HS, Jang KL. Activation of the human endogenous retrovirus W long terminal repeat by herpes simplex virus type 1 immediate early protein 1. Mol Cells 2003, 15:75-80.
88. Sjottem E, Anderssen S, Johansen T. The promoter activity of long terminal repeats of the HERV-H family of human retrovirus-like elements is critically dependent on Sp1 family proteins interacting with a GC/GT box located immediately 30 to the TATA box. J Virol 1996, 70:188-98. 189804, 8523525.
89. Menendez L, Benigno BB, McDonald JF. L1 and HERV-W retrotransposons are hypomethylated in human ovarian carcinomas. Mol Cancer 2004, 3:12. 10.1186/1476-4598-3-12, 411053, 15109395.
90. Florl AR, Lower R, Schmitz-Drager BJ, Schulz WA. DNA methylation and expression of LINE-1 and HERV-K provirus sequences in urothelial and renal cell carcinomas. Br J Cancer 1999, 80:1312-21. 10.1038/sj.bjc.6690524, 2363067, 10424731.
91. Lavie L, Kitova M, Maldener E, Meese E, Mayer J. CpG methylation directly regulates transcriptional activity of the human endogenous retrovirus family HERV-K(HML-2). J Virol 2005, 79:876-83. 10.1128/JVI.79.2.876-883.2005, 538560, 15613316.
92. International Agency for Research on Cancer (IARC) Globocan 2008 Available at: http://globocan.iarc.fr. Accessed in November 2012, International Agency for Research on Cancer (IARC).
93. McPherson K, Steel CM, Dixon JM. ABC of breast diseases. Breast cancer epidemiology, risk factors and genetics. BMJ 2000, 321:624-628. 10.1136/bmj.321.7261.624, 1118507, 10977847.
94. Kelsey JL, Bernstein L. Epidemiology and prevention of breast cancer. Annu Rev Public Health 1996, 17:47-67. 10.1146/annurev.pu.17.050196.000403, 8724215.
95. Hulka BS, Moorman PG. Breast cancer: hormones and other risk factors. Maturitas 2001, 38:103-113. discussion 113-106, 10.1016/S0378-5122(00)00196-1, 11311599.
96. Savu A, Potter J, Li S, Yasui Y. Breast cancer and microbial cancer incidence in female populations. Int J Cancer 2008, 123:1094-1099. 10.1002/ijc.23595, 18537160.
97. Ejthadi HD, Martin JH, Junying J, et al. A novel multiplex RT-PCR system detects human endogenous retrovirus-K in breast cancer. Arch Virol 2005, 150(1):177-184. 10.1007/s00705-004-0378-8, 15449135.
98. Golan M, Hizi A, Resau JH, et al. Human endogenous retrovirus (HERV-K) reverse transcriptase as a breast cancer prognostic marker. Neoplasia 2008, 10(6):521-533. 2386537, 18516289.
99. Hill AB. The environment and disease: association or causation?. Proc R Med Soc 1965, 58:295-300.
100. Shack L, Jordan C, Thomson ST, Mak V, Møller H. Variation in incidence of breast, lung and cervical cancer and malignant melanoma of skin by socioeconomic group in England. BMC Cancer 2008, 8:271. 10.1186/1471-2407-8-271, 2577116, 18822122.
101. Markovic SN, Erickson LA, Rao RD, Weenig RH, Pockaj BA, Bardia A, et al. Malignant melanoma in the 21st century. Part 1. Epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin Proc 2007, 82:364-80.
102. Yost K, Perkins C, Cohen R, Morris C, Wright W. Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control 2011, 12:703-711.
103. Pukkala E, Weiderpass E. Time trends in socio-economic differences in incidence rates of cancers of the breast and female genital organs (Finland, 1971-1995). Int J Cancer 1999, 81:56-61. 10.1002/(SICI)1097-0215(19990331)81:1<56::AID-IJC11>3.0.CO;2-4, 10077153.
104. G F, PL L, P M, Colombo MP. Immunoprevention of Cancer: Is the Time Ripe?. Cancer Res 2000, 60:2571-2575.
105. Roukens AH, Visser LG. Yellow fever vaccine: past, present and future. Expert Opin Biol Ther 2008, 8:1787-95. 10.1517/14712598.8.11.1787, 18847312.
106. Pulendran B. Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat Rev Immunol 2009, 9(10):741-7.